TRICARE Prior Authorization Request Form for teriparatide (Forteo)



JOHNS HOPKINS HEALTHCARE

7231 Parkway Drive, Suite 100, Hanover, MD 21076

FAX Completed Form and Applicable Progress Notes to: (410) 424-4037

USFHP Pharmacy Prior Authorization Form

To be completed by Requesting provider			
Drug Name:	Strength:		
Dosage/Frequency (SIG):	Duration of Therapy:		

Questions? Contact the Pharmacy Dept at: (888) 819-1043, option 4

Clinical Documentation must accompany form in order for a determination to be made.

Step	Please complete patient and physician information (please print):				
1	Patient	Name: Physi	Physician Name:		
	Address:		Address:		
	Sponso	or ID #	Phone #:		
	Date of	f Birth: Se	Secure Fax #:		
Step	Please complete the clinical assessment:				
2	Is the patient GREATER THAN or EQUAL to 18 years of age?	· · · · · · · · · · · · · · · · · · ·	□ Yes	□ No	
		Proceed to question 2	STOP		
				Coverage not approved	
	2. Is Forteo being prescribed for treatment of osteoporosis, and not for prevention of osteoporosis?	□ Yes	□ No		
		Proceed to question 3	STOP		
				Coverage not approved	
	3. Is the patient a postmenopausal female with osteoporosis?	□ Yes	□ No		
		osteoporosis ?	Proceed to question 6	Proceed to question 4	
	4. Is the patient male with primary or hypogonadal osteoporosis?	□ Yes	□ No		
		Proceed to question 6	Proceed to question 5		
	5. Does the patient have osteoporosis associated with sustained systemic glucocorticoid therapy (e.g., GREATER THAN 6 months use of GREATER THAN 7.5mg/day prednisone or equivalent)?	□ Yes	□ No		
		Proceed to question 6	STOP		
			Coverage not approved		
	6. Is the patient at high risk for fracture defined as one of the following; history of osteoporotic fracture, multiple risk factors for fracture (e.g., a history of	□ Yes	□ No		
		Proceed to question 9	Proceed to question 7		
		vertebral fracture or low-trauma fragility fracture of the hip, spine or pelvis, distal forearm or proximal humerus)?			

TRICARE Prior Authorization Request Form for teriparatide (Forteo)

	7.	Does the patient have a bone mineral density (BMD) T-score of -2.5 or worse?	□ Yes	□ No
		1-score of -2.5 or worse?	Proceed to question 9	Proceed to question 8
	8. Has the patient tried and experienced an inadequate response to, therapeutic failure with, is intolerant to	□ Yes	□ No	
		(unable to use or absorb), or has contraindications to	Proceed to question 9	STOP
	at least one formulary osteoporosis therapy (e.g., alendronate, ibandronate)?		Coverage not approved	
	9. Will the patient continue to take calcium and vitamin D supplementation during PTH analog therapy if dietary intake is inadequate?	□ Yes	□ No	
			Proceed to question 10	STOP
				Coverage not approved
	10.). Will the cumulative treatment with Forteo and Tymlos	□ Yes	□ No
		exceed 24 months during the patient's lifetime?	STOP	Proceed to question 11
			Coverage not approved	
	11.	Is the patient at increased risk for osteosarcoma (e.g., Paget's disease, unexplained elevations of alkaline	□ Yes	□ No
		phosphatase, patients with open epiphyses, prior	STOP	Sign and date below
		external beam or implant radiation therapy involving the skeleton)?	Coverage not approved	
Step	I certif	fy the above is true to the best of my knowledg	je. Please sign and d	ate:
3				
		Prescriber Signature	Date	
				[8 May 2019]
or Intern	nal Use C	Only		
] Approv	Approved:		Duration of Approval:month(s)	
] Denied	Denied:		Authorized By:	
Incomplete/Other:			PA#:	
ate Faxed to MD:			Date Decision Rendered:	